Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 6,679 shares, a decrease of 66.1% from the November 30th total of 19,690 shares. Based on an average daily volume of 34,557 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.3% of the shares of the stock are short sold. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily volume of 34,557 shares, the days-to-cover ratio is presently 0.2 days.

Xenetic Biosciences Stock Performance

Shares of XBIO stock opened at $2.19 on Friday. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93. The stock has a market capitalization of $5.02 million, a PE ratio of -1.07 and a beta of 2.40. The stock’s fifty day moving average is $2.75 and its 200-day moving average is $3.24.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.16. Xenetic Biosciences had a negative net margin of 110.42% and a negative return on equity of 64.66%. The business had revenue of $1.03 million for the quarter. As a group, analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Sachetta LLC lifted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,259 shares of the company’s stock after purchasing an additional 4,593 shares during the period. Sachetta LLC owned 0.99% of Xenetic Biosciences worth $60,000 at the end of the most recent quarter. Institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.